



# Biotech Daily

Tuesday November 2, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: TELIX UP 8%; PHARMAXIS DOWN 8%**
- \* **TELIX: TGA 1st ILLUCCIX FOR PROSTATE CANCER IMAGING APPROVAL**
- \* **MEDADVISOR \$4m US PILOT SARS-COV-2 VACCINATION PROGRAM**
- \* **ISRAEL APPROVES MGC CIMETRA DOSING STUDY**
- \* **NEUROSCIENTIFIC: BIOSPECTIVE TO RUN EMTINB MS STUDIES**
- \* **IMMUTEP: CHINA PATENT FOR IMP321 COMBINATION**
- \* **OSTEOPORE: CHINA PATENT FOR BONE SCAFFOLD METHOD**
- \* **HEXIMA 2.8m DIRECTOR OPTIONS AGM**
- \* **PERENNIAL TAKES 7.5% OF ECOFIBRE**

## MARKET REPORT

The Australian stock market fell 0.63 percent on Tuesday November 2, 2021, with the ASX200 down 46.5 points to 7,324.3 points.

Twelve of the Biotech Daily Top 40 stocks were up, 23 fell, four traded unchanged and one was untraded.

Telix was the best for the second day in a row, up 54 cents or 8.1 percent to \$7.18, with 762,045 shares traded. Resonance and Volpara climbed more than four percent; Actinogen was up 3.6 percent; Avita and Pro Medicus rose more than two percent; Imugene was up one percent; with Cochlear, CSL, Immutep, Kazia, Medical Developments, Neuren and Opthea up by less than one percent.

Pharmaxis led the falls, down one cent or eight percent to 11.5 cents with 156,388 shares traded. Amplia and Uscom lost more than seven percent; Osprey shed 6.7 percent; Impedimed, Patrys and Prescient were down five percent or more; Antisense, Cyclopharm and LBT fell more than four percent; Alterity was down 3.45 percent; Dimerix, Nova Eye, Oncosil, Optiscan, Polynovo and Universal Biosensors shed two percent or more; Clinuvel and Proteomics were down more than one percent; with Genetic Signatures, Nanosonics, Next Science, Resmed and Starpharma down by less than one percent.

## TELIX PHARMACEUTICALS

Telix says the Australian Therapeutic Goods Administration has granted the first approval for its Illuccix for diagnostic imaging of men with prostate cancer.

Telix said the TGA had granted “a broad clinical indication” including patients at risk of metastasis suitable for initial definitive therapy, or “primary staging”, as well as patients suspected of recurring prostate cancer based on elevated antigen serum levels, also known as “biochemical recurrence”.

The company said the TGA Illuccix approval facilitated “wide-spread clinical access to prostate cancer imaging for all men across Australia including rural and regional areas” enabling availability of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging across the country.

Telix Asia Pacific region head Dr David Cade said the approval “means Australian patients with prostate cancer will have broad access to a TGA-approved PSMA-PET imaging agent”.

“This new mode of imaging has been recognized in leading clinical practice guidelines as superior to conventional imaging with [computed tomography or magnetic resonance imaging] for the staging of prostate cancer,” Dr Cade said.

“Illuccix attaches to prostate cancer cells expressing PSMA and can be picked up by a PET scanner, giving physicians the ability to visualize tumor cells, including very small metastases, wherever they are in the body”, said Dr Cade.

Telix chief executive officer Dr Christian Behrenbruch said that PSMA-PET imaging was “one of the most important developments in prostate cancer management in recent years”.

“As an Australian company, we are especially pleased to be delivering the first TGA-approved, [good manufacturing practice] manufactured PSMA-PET imaging agent that will be widely available to Australian patients,” Dr Behrenbruch said.

“The TGA is a sophisticated regulatory authority that is highly regarded in the Asia Pacific region,” Dr Behrenbruch said.

“This approval is an important milestone for Telix, demonstrating the approvability of Illuccix and establishing a blueprint for a series of near-term regulatory submissions and reviews in other important markets across the Asia Pacific,” Dr Behrenbruch said.

A Telix spokesperson told Biotech Daily that US Food and Drug Administration approval of Illuccix was expected by the end of this year.

Telix was up 54 cents or 8.1 percent to \$7.18 with 762,045 shares traded.

## MEDADVISOR

Medadvisor says it has a \$US3 million (\$A4 million) unnamed customer pilot program to provide digital Covid-19 education in US states where vaccine uptake was low.

Medadvisor said the program was with an unnamed existing customer which was “a top-10 pharmaceutical manufacturer... with a market capitalization exceeding \$A200 billion”.

The company said the program would run from this year through pharmacy chains “to target and educate certain demographics in states where Covid-19 vaccination rates are low” and was expected to be completed by July 2022.

Medadvisor managing-director Robert Read said the severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) vaccination rates varied “substantially across different states in the US and there are a number of geographies and particular demographics that will benefit from text messages to educate patients on the availability of vaccines”

“This is our largest digital program in the US to date and if successful would scale well across our network,” Mr Read said.

Medadvisor was up one cent or 2.8 percent to 37 cents with 1.1 million shares traded.

## MGC PHARMACEUTICALS

MGC says it has ethics approval for a 240-patient, 28-day dosing study of its Cimetra compound for Covid-19 at the Haifa, Israel-based Rambam Medical Centre.

MGC said the study would establish the most effective concentrations of Cimetra's active ingredients, which included *Curcuma longa*, or turmeric, and *Boswellia serrata*, or Indian frankincense.

The company said the trial would include safety and pharmacokinetic profiling to support regulatory approvals.

MGC said that the double-blind, placebo-controlled study would compare spray administration of low dose Cimetra against high dose Cimetra and a placebo – all “as an add-on therapy” for patients with Covid-19.

MGC fell 0.1 cents or 2.1 percent to 4.7 cents with 6.7 million shares traded.

## NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says it has hired the Montreal, Québec-based Biospective Inc to run its studies of Emtinb for multiple sclerosis.

Neuroscientific said that Biospective performed pre-clinical and clinical neurology imaging for neurodegenerative diseases, such as multiple sclerosis.

Neuroscientific managing-director Matt Liddelow said “the range of imaging technologies offered by Biospective is unprecedented for pre-clinical neurology research and will aid in generating detailed data that will be of clinical significance in future clinical studies”.

Neuroscientific was up 1.5 cents or 4.4 percent to 35.5 cents.

## IMMUTEP

Immutep says the China Patent Office has granted a patent for its IMP321 and a chemotherapy agent in combination to manufacture a treatment of cancer.

Immutep said that the patent, titled ‘Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response’ would protect its intellectual property until October 3, 2028.

The company said that the patent claim related to use of IMP321, also known as efitlagimod alpha or efiti, and was owned by Immutep SAS, and would be exclusively licenced to Immutep's China partner EOC Pharma.

Immutep was up half a cent or 0.85 percent to 59 cents with 2.5 million shares traded.

## OSTEOPORE

Osteopore says the China Patent Office has granted a patent covering the method of construction of its scaffolds to promote bone growth.

Osteopore said that the patent was titled ‘Bio-resorbable magnesium composite’ but did not disclose the duration of the patent.

Biotech Daily contacted the company for clarification but had not received a reply at the time of publication.

Osteopore said the patent was co-developed with researchers from Nanyang Technological University, Singapore and described “the process by which a magnesium filler comprised of a soluble magnesium salt - magnesium phosphate ( $Mg_3(PO_4)_2$ ) - is produced as a thin film, and when combined with a suitable polymer, is used to produce smart three-dimensional biomimetic scaffolds without requiring solvents or heat”.

Osteopore was up one cent or 4.3 percent to 24.5 cents.

## HEXIMA

Hexima says its annual general meeting will vote to grant seven directors a total of 2,789,500 options, vesting under various conditions.

Hexima said shareholders would vote to issue Jason Nunn 536,500 options, conditional on his election as director, exercisable at 27.5 cents by September 1, 2031.

The company said the meeting would vote to issue executive director Michael Aldridge 522,000 options, Prof Jonathan West 393,000 options, with 224,000 options each to Scott Robertson and Justin Yap, Dr Nicole van der Weerden 244,000 options, with 36,000 options for Prof Marilyn Anderson, all exercisable at 20.5 cents each by July 27, 2031.

The company said its shareholders would also consider the company's remuneration report, the election of directors Dr van der Weerden and Messrs Yap and Nunn, the

approval of a 10 percent placement facility, and the approval of capital raising measures.

The virtual meeting will be held on December 2, 2021, at 11am (AEDT) and is available at:

<https://meetings.linkgroup.com/HXL21>.

Hexima was unchanged at 37 cents.

## ECOFIBRE

Perennial Value Management says it has increased its substantial shareholding in Ecofibre from 22,040,638 shares (6.46%) to 26,276,118 shares (7.53%).

The Sydney-based Perennial Value Management said it bought and sold shares between September 27, 2021, and October 28, 2021 with the single largest purchase 1,437,991 shares for \$965,574 or 67.15 cents a share.

Ecofibre was up 2.5 cents or 3.25 percent to 79.5 cents.